Notably, the levels of CD19+IgM+IgD− B cells were significantly increased in patients with CLL, 57.21% (66.02–52.63) when compared to the control group 36.02% (40.97–28.41), p = 0.0083 (Fig. 2C). This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.